The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible to participate in an exciting new clinical trial. NMD Pharma, a biotechnology company, has received approval from the U.S. Food and Drug Administration (FDA) to launch the SYNAPSE-CMT Phase 2 trial. This trial will evaluate the safety, tolerability, and potential effectiveness of an investigational medication, NMD670, which could improve muscle strength and endurance in individuals with CMT.
What is the Goal of the Study?
NMD670 is a skeletal muscle targeted therapy that inhibits the action of chloride-1 ion channels that reside in the skeletal muscle membrane. It is in oral capsule form taken twice daily and works by enhancing communication between nerves and muscles where transmission is impaired, a common issue for people living with CMT. The hope is that this treatment will improve your strength, endurance, and overall daily functioning. By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future. Learn more or to participate: https://clinicaltrials.gov/study/NCT06482437 https://lnkd.in/eHsEZ6MP